정부/공공기관
임상시험센터
CRO
분석CRO/센트럴랩
유관기관/협회
정보서비스
해외 유관 기관
* CRO 게재 기준: CRO자율등록 기관
ClinicalTrials.gov에 등록된 정보를 기준으로 코로나-19(COVID-19) 관련 글로벌 임상시험 현황을 제공합니다.
전체 2550건이 검색되었습니다.
| No. | Status | Study Title | Conditions | Interventions | Phase | Sponsor/Collaborators | Funder Type | Number Enrolled | Sex | Age | Locations |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1493 | Active, not recruiting | Efficacy, Safety and Immunogenicity of Inactivated SARS-CoV-2 Vaccines (Vero Cell) to Prevent COVID-19 in Healthy Adult Population In Peru Healthy Adult Population In Peru | COVID-19 | Biological: Inactivated SARS CoV 2 vaccine (Vero cell) Wuhan/Beijing/Placebo | Phase 3 | Universidad Peruana Cayetano Heredia, National University of San Marcos, Peru | OTHER | 12000 | All | 18 Years | Av. Honorio Delgado 430, Urb. Ingenieria, San Martin De Porres, Lima, Peru |
| 1492 | Completed | Efficacy, Safety and Immunogenicity Study of SARS-CoV-2 Inactivated Vaccine | SARS-CoV2 Infection | Biological: SARS-CoV-2 vaccine (inactivated) Biological: Placebo |
Phase 3 | PT Bio Farma, Faculty of Medicine Universitas Padjadjaran, National Intitute of Health Research and Development, Ministry of Health Republic of Indonesia, Sinovac Life Sciences Co., Ltd. | INDUSTRY | 1620 | All | 18 Years ~ 59 Years | Hasan Sadikin Hospital/School of Medicine, Padjadjaran University, Bandung, West Java, Indonesia |
| 1491 | Completed | Efficacy, Safety and Tolerability of Ivermectin in Subjects Infected With SARS-CoV-2 With or Without Symptoms | COVID-19 | Drug: Ivermectin Drug: Placebo |
Phase 2 | Investigacion Biomedica para el Desarrollo de Farmacos S.A. de C.V. | OTHER | 66 | All | 18 Years | Investigacion Biomedica para el Desarrollo de Farmacos S.A. de C.V., Zapopan, Jalisco, Mexico |
| 1490 | Recruiting | Efficacy, Safety, and Immunogenicity of Two Vaccination Schedules of an Inactivated Vaccine Against COVID-19 in Adults | Vaccines | Biological: SARS-CoV-2 inactivated vaccine | Phase 3 | Pontificia Universidad Catolica de Chile, Ministry of Health, Chile, Sinovac Biotech Co., Ltd | OTHER | 2300 | All | 18 Years | Centro de Especialidades Medicas, Red de Salud UC Christus, Santiago, RM, Chile |
| 1489 | Not yet recruiting | Efficacy, Safety, and Immunogenicity of Vaccine Reimmunization With a Third Homologous Versus Heterologous Dose Against SARS-CoV-2 in Patients Undergoing Solid Organ Transplantation. | Covid19 | Biological: Janssen vaccine Biological: Spikevax (Moderna) vaccine |
Phase 3 | Instituto de Investigacion Marques de Valdecilla | OTHER | 386 | All | 18 Years | Hospital Universitario Marques de Valdecilla, Santander, Cantabria, Spain |
| 1488 | Not yet recruiting | Efficacy, Safety, and Immunogenicity Study of the Recombinant Two-component COVID-19 Vaccine (CHO Cell) | COVID-19 | Biological: Recombinant two-component COVID-19 vaccine (CHO cell) Biological: Placebo |
Phase 3 | Jiangsu Rec-Biotechnology Co., Ltd. | INDUSTRY | 20301 | All | 18 Years ~ 80 Years | |
| 1487 | Recruiting | Efficacy, Safety, Tolerability, and Biomarkers of MN-166 (Ibudilast) in Patients Hospitalized With COVID-19 and at Risk for ARDS | Pneumonia, Viral | Drug: Ibudilast Drug: Placebo |
Phase 2 | MediciNova | INDUSTRY | 40 | All | 18 Years ~ 80 Years | Denver Health and Hospital Authority, Denver, Colorado, United States Yale University School of Medicine, New Haven, Connecticut, United States |